Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes. The aim of the C-SWIFT study was to identify the minimum effective treatment duration across multiple genotypes. C-SWIFT was an open-label, single-center trial in treatment-naïve patients with chronic HCV genotype (GT)1 or 3 infection. All patients received elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4-12 weeks. Patients with GT1 infection who failed therapy were eligible for retreatment with EBR/GZR+SOF and ribavirin for 12 weeks. The primary efficacy endpoint was sustained virological response [SVR]12 (SVR of HCV RNA <15 IU/mL 12 weeks after the end of therapy). Rates of SVR12 were 32% (10 of 31) and 87% (26 of 30) in patients without cirrhosis with GT1 infection treated for 4 and 6 weeks and 80% (16 of 20) and 81% (17 of 21) in GT1-infected patients with cirrhosis treated for 6 and 8 weeks. Among GT3-infected patients without cirrhosis, SVR12 was 93% (14 of 15) and 100% (14 of 14) after 8 and 12 weeks. SVR12 in GT3-infected patients with cirrhosis was 83% (10 of 12) after 12 weeks of treatment. Twenty-three GT1-infected patients who relapsed following initial treatment completed retreatment; all achieved SVR12. In the initial treatment phase, there was one serious adverse event of pneumonia, which led to treatment discontinuation, and during retreatment, 1 patient discontinued ribavirin because of pruritus. CONCLUSION: Data from this study support the use of 8-week treatment regimens that maintain high efficacy, even for patients with HCV GT3 infection. Retreatment of patients who failed short-duration therapy was achieved through extended treatment duration and addition of ribavirin. (Hepatology 2017;65:439-450).
Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes. The aim of the C-SWIFT study was to identify the minimum effective treatment duration across multiple genotypes. C-SWIFT was an open-label, single-center trial in treatment-naïve patients with chronic HCV genotype (GT)1 or 3 infection. All patients received elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4-12 weeks. Patients with GT1 infection who failed therapy were eligible for retreatment with EBR/GZR+SOF and ribavirin for 12 weeks. The primary efficacy endpoint was sustained virological response [SVR]12 (SVR of HCV RNA <15 IU/mL 12 weeks after the end of therapy). Rates of SVR12 were 32% (10 of 31) and 87% (26 of 30) in patients without cirrhosis with GT1 infection treated for 4 and 6 weeks and 80% (16 of 20) and 81% (17 of 21) in GT1-infected patients with cirrhosis treated for 6 and 8 weeks. Among GT3-infected patients without cirrhosis, SVR12 was 93% (14 of 15) and 100% (14 of 14) after 8 and 12 weeks. SVR12 in GT3-infected patients with cirrhosis was 83% (10 of 12) after 12 weeks of treatment. Twenty-three GT1-infected patients who relapsed following initial treatment completed retreatment; all achieved SVR12. In the initial treatment phase, there was one serious adverse event of pneumonia, which led to treatment discontinuation, and during retreatment, 1 patient discontinued ribavirin because of pruritus. CONCLUSION: Data from this study support the use of 8-week treatment regimens that maintain high efficacy, even for patients with HCV GT3 infection. Retreatment of patients who failed short-duration therapy was achieved through extended treatment duration and addition of ribavirin. (Hepatology 2017;65:439-450).
Authors: Sarah E Van Pilsum Rasmussen; Shanti Seaman; Diane Brown; Niraj Desai; Mark Sulkowski; Dorry L Segev; Christine M Durand; Jeremy Sugarman Journal: AJOB Empir Bioeth Date: 2019-10-16
Authors: Hwa-Ping Feng; Luzelena Caro; Christine Fandozzi; Xiaoyan Chu; Zifang Guo; Jennifer Talaty; Deborah Panebianco; Katherine Dunnington; Lihong Du; William D Hanley; Iain P Fraser; Anna Mitselos; Jean-Francois Denef; Inge De Lepeleire; Jan N de Hoon; Corinne Vandermeulen; William L Marshall; Patricia Jumes; Xiaobi Huang; Monika Martinho; Robert Valesky; Joan R Butterton; Marian Iwamoto; Wendy W Yeh Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.938
Authors: Christine M Durand; Mary G Bowring; Diane M Brown; Michael A Chattergoon; Guido Massaccesi; Nichole Bair; Russell Wesson; Ashraf Reyad; Fizza F Naqvi; Darin Ostrander; Jeremy Sugarman; Dorry L Segev; Mark Sulkowski; Niraj M Desai Journal: Ann Intern Med Date: 2018-03-06 Impact factor: 51.598
Authors: Thomas N Kakuda; Matthew W McClure; Christopher Westland; Jennifer Vuong; Marie-Claude Homery; Gwendoline Poizat; Laure Viguerie; Caroline Denot; Alain Patat; Qingling Zhang; James Hui; David Apelian; David B Smith; Sushmita M Chanda; John Fry Journal: Pharmacol Res Perspect Date: 2018-04-30